AVENUE THERAPEUTICS INC (ATXI)       1.52  +0.02 (+1.33%)

1.52  +0.02 (+1.33%)

US05360L3042 - Common Stock - After market: 1.53 +0.01 (+0.66%)

AVENUE THERAPEUTICS INC1.52

NASDAQ:ATXI (12/6/2022, 7:22:38 PM)+0.02 (+1.33%)

After market: 1.53 +0.01 (+0.66%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Pharmaceuticals
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-10 2022-11-10/amc Earnings (Next) N/A N/A
Ins Owners 26.84% Inst Owners 0%
Market Cap 7.26M Shares 4.77M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 43.33
IPO 06-27 2017-06-27

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ATXI Daily chart

Company Profile

Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2017-06-27. The firm seeks to develop and commercialize its product principally for use in the acute/intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol, for the treatment of post-operative acute pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. The company also works through the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. These opioid and non-opioid modes of action are synergistic, providing multimodal therapy with the use of a single drug. Tramadol is marketed as an oral agent indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Ultracet, a combination product containing tramadol and acetaminophen, is also marketed in the United States (Ortho-McNeil-Janssen).

Company Info

AVENUE THERAPEUTICS INC

2 Gansevoort St Fl 9

New York City NEW YORK 10036

P: 17816524500.0

CEO: Lucy Lu

Employees: 4

Website: http://www.avenuetx.com/

ATXI News

News Imagea month ago - Avenue TherapeuticsAvenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company...

News Imagea month ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day with an overview of the biggest pre-market stock movers traders need to know about for Thursday!

News Imagea month ago - Avenue TherapeuticsAvenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders

NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company...

News Image2 months ago - AB NewswireHillcrest ($HLRTF) and Hercules set to collaborate to build and test an electric powertrain for a range of e-mobility productsNews Image2 months ago - Avenue TherapeuticsAvenue Therapeutics Announces Closing of $12 Million Underwritten Public Offering

NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company...

ATXI Twits

Here you can normally see the latest stock twits on ATXI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example